best of the rest

MassChallenge Texas names its top 10 companies in its Houston cohort

These are the 10 finalists heading to MassChallenge's virtual awards program next month. Photo courtesy of MassChallenge

Boston-based MassChallenge has named its top picks from its second Houston cohort ahead of its awards event. This year's programming, due to the pandemic, was held completely online.

"Great entrepreneurs don't let a crisis go to waste: this cohort was assembled from virtually every industry across 13 different countries and through the twists and turns, their passion became a beacon for the future," says Jon Nordby, managing director of MassChallenge Texas in Houston. "These top startups represent the best qualities of all of us: resilient, ingenious, and able to push ourselves further than we think we are capable. They embody the entrepreneurial spirit that brings hope and progress to society."

The 10 companies — which represent the top 18 percent of the cohort — will now compete in a final round of judging for up to $250,000 in equity-free cash prizes. The winners will be revealed at the 2020 MassChallenge Virtual U.S. Awards, which will be held online.

The 2020 MassChallenge Texas in Houston top 10 finalists are:

  • B2B Pay, based in Helsinki, Finland, is a fintech startup with a multi-bank platform.
  • FloodFrame, based in Richmond just outside of Houston, is a self-deploying flood protection system that can be easily installed to existing houses.
  • Healium, based in Columbia, Missouri, is an extended reality device created for self-management of anxiety.
  • Houston-based Integricote uses nanotechnology research that originated from the University of Houston in the treatment and fortification of materials like wood and concrete.
  • Ozark Integrated Circuits Inc., based in Fayetteville, Arkansas, specializes in problem solving using technology and software in the harshest environments – from jet engines to earth orbit.
  • Houston-based PATH EX Inc. is focused on the rapid diagnosis and treatment of sepsis through a pathogen extraction platform.
  • PREEMIEr Diagnostics, based in Southfield, Michigan, created a way to identify which premature infants need an adjustment to their glucose levels to prevent them from losing vision.
  • Scout Inc., based in Alexandria, Virginia, is developing the first commercial in-space satellite inspection service.
  • Sunnydale, California-based Sizzle is using artificial intelligence to automatically create gaming highlights for the billion gaming viewers.
  • Starling Medical, based in Houston, has tapped into tech to optimize urinary catheter for patients with neurogenic bladder dysfunction.

The 54-company cohort, which is the second based in Houston since the program's launch last year, was challenged early on — much like the other MassChallenge cohorts — to pivot to virtual acceleration over the four-month experience.

Robert Pieroni, director of Economic Development for Central Houston, which was part of the group that worked to bring MCTX to Houston, says he sees a need for this type of accelerator now more than ever.

"MassChallenge's work sources ground-breaking ideas from around the world and invites them into an inclusive village surrounded by a network of tools, resources, and opportunities that help founders accelerate and scale their business to solve humankind's boldest challenges head-on," he says. "The addition of virtual and the rise of distributed teams in response to the pandemic will make it easier for startups to launch and build businesses anywhere."

MassChallenge's Houston cohort will be one of a few featured at the virtual awards event on October 22 at 4 p.m. Headliners for the event include Arianna Huffington, founder and CEO of Thrive Global, and Linda Pizzuti Henry, managing director of the Boston Globe, and Chris Denson of Innovation Crush will be the host. For more information about the event and to register, visit the MassChallenge website.

Trending News

Building Houston

 
 

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Trending News